National Research reports Q2 2023 diluted EPS $0.29, down from $0.33 YoY; new sales up 53%

NRC HEALTH

2023-Q2 EPS reported $0.58 revenue$72,634,000

Diluted EPS $0.29 for Q2 2023 vs $0.33 for Q2 2022, a 12% decrease.
New sales increased 53% compared to Q2 2022.
Human Understanding Program adopted by 39 healthcare organizations through June 30.
Capital allocation: $4.2M innovation/growth, $3.0M dividends, $1.8M share repurchases in Q2.
Operating margins improved in Q2 2023 compared to Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NRC HEALTH reported second quarter ended June 30, 2023 results: EPS $0.29.

Period: second quarter ended June 30, 2023
EPS: $0.29
Result: reported results

Exact text from the filing

Diluted earnings per share decreased to $0.29 for the quarter ended June 30, 2023, from diluted earnings per share of $0.33 for the quarter ended June 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

NRC HEALTH filing history →

Source: SEC EDGAR

accession 0001437749-23-021779

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.